Ballentine Partners LLC Acquires New Holdings in Qiagen (NYSE:QGEN)

Ballentine Partners LLC acquired a new position in Qiagen (NYSE:QGEN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 5,405 shares of the company’s stock, valued at approximately $241,000.

A number of other hedge funds also recently bought and sold shares of the stock. Wellington Management Group LLP increased its holdings in shares of Qiagen by 77.7% in the 3rd quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock valued at $963,386,000 after acquiring an additional 9,293,040 shares during the period. Victory Capital Management Inc. boosted its position in Qiagen by 62.6% during the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock valued at $117,329,000 after purchasing an additional 991,325 shares in the last quarter. State Street Corp grew its stake in Qiagen by 3.9% in the third quarter. State Street Corp now owns 2,380,008 shares of the company’s stock valued at $108,457,000 after purchasing an additional 90,181 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Qiagen by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock worth $105,726,000 after purchasing an additional 324,417 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Qiagen by 170.6% during the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock valued at $84,259,000 after buying an additional 1,165,594 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 0.3 %

Shares of QGEN stock opened at $45.70 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.93. The firm has a market capitalization of $10.43 billion, a PE ratio of 117.18, a P/E/G ratio of 3.49 and a beta of 0.37. The stock’s 50-day simple moving average is $44.60 and its 200-day simple moving average is $44.30.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $54.00 price objective (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $48.00 price target (down from $50.00) on shares of Qiagen in a research report on Monday, January 6th. Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.50.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.